Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Faller

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2023
External Validation of Risk Factors for Unplanned Hospitalization in Older Adults With Advanced Cancer Receiving ChemotherapyMostafa R Mohamed, Kah Poh Loh, Supriya G Mohile, et al.
Journal of the National Cancer Institute|May 22, 2024
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)Howard S Hochster, Paul Catalano, Michelle Weitz, et al.
Clinical Lung Cancer|March 22, 2021
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811)Athanassios Argiris, Jieling Miao, Mihaela C Cristea, et al.
Nature Medicine|October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trialAlain P Algazi, Megan Othus, Adil I Daud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2024
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929Nagla Abdel Karim, Jieling Miao, Karen L Reckamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2023
Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal AdenocarcinomaWilliam A Hall, Jiahe Li, Y Nancy You, et al.
Cancer|December 10, 2021
A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152)Angela R Bradbury, Ju-Whei Lee, Jill Bennett Gaieski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2021
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research GroupRoisin M Connolly, Fengmin Zhao, Kathy D Miller, et al.
JAMA Oncology|July 1, 2021
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical TrialOsama E Rahma, Greg Yothers, Theodore S Hong, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2023
External Validation of Risk Factors for Unplanned Hospitalization in Older Adults With Advanced Cancer Receiving ChemotherapyMostafa R Mohamed, Kah Poh Loh, Supriya G Mohile, et al.
Journal of the National Cancer Institute|May 22, 2024
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)Howard S Hochster, Paul Catalano, Michelle Weitz, et al.
Clinical Lung Cancer|March 22, 2021
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811)Athanassios Argiris, Jieling Miao, Mihaela C Cristea, et al.
Nature Medicine|October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trialAlain P Algazi, Megan Othus, Adil I Daud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2024
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929Nagla Abdel Karim, Jieling Miao, Karen L Reckamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2023
Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal AdenocarcinomaWilliam A Hall, Jiahe Li, Y Nancy You, et al.
Cancer|December 10, 2021
A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152)Angela R Bradbury, Ju-Whei Lee, Jill Bennett Gaieski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2021
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research GroupRoisin M Connolly, Fengmin Zhao, Kathy D Miller, et al.
JAMA Oncology|July 1, 2021
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical TrialOsama E Rahma, Greg Yothers, Theodore S Hong, et al.
Pageof 8